New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4504-4515

  Gueugnon, Fabien ^a,b,c   Cartron, Pierre François ^a,b,d   Charrier, Cedric ^b,e   Bertrand, Philippe ^b,d,e   Fonteneau, Jean François ^a,b,c   Gregoire, Marc ^a,b,c   Blanquart, Christophe ^a,b,d  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d Réseau Epigénétique du Canceropôle Grand Ouest   (France)

^e UNIVERSITÉ DE POITIERS   (France)

Author keywords

Chemotherapy and epigenetic; Lung cancer; Mesothelioma

Indexed keywords

4 METHYL 5 (2 METHYL 3OXO 2,3 DIHYDRO BENZOFURAN 2 YL)PENTA 2,4 DIENOIC ACID BENZAMIDE; 4 METHYL 5 (2 METHYL 3OXO 2,3 DIHYDRO BENZOFURAN 2 YL)PENTA 2,4 DIENOIC ACID HYDROXAMIDE; 5 (6 DIMETHYLAMINO 2 METHYL 3OXO 2,3 DIHYDRO BENZOFURAN 2 YL) 4 METHYL PENTA 2,4 DIENOIC ACID BENZAMIDE; 5 (6 DIMETHYLAMINO 2 METHYL 3OXO 2,3 DIHYDRO BENZOFURAN 2 YL) 4 METHYLPENTA 2,4 DIENOIC ACID HYDROXAMIDE; BENZAMIDE; CISPLATIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; MESSENGER RNA; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG ADENOCARCINOMA; PHENOTYPE; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; THORAX CANCER; METABOLISM; THORAX TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; HISTONE DEACETYLASE INHIBITORS; HUMANS; THORACIC NEOPLASMS;

EID: 84905105547     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2056     Document Type: Article

References (42)

1. Siesling, van der Zwan, Izarzugaza, Jaal, Treasure, Foschi, Ricardi, Groen, Tavilla, Ardanaz: Rare thoracic cancers, including peritoneum mesothelioma. Eur J Cancer. 2012; 48: 949-960.
2. Travis, Brambilla, Noguchi, Nicholson, Geisinger, Yatabe, Beer, Powell, Riely, Van Schil, Garg, Austin, Asamura, Rusch, Hirsch, Scagliotti, et al: International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011; 6: 244-285.
3. Scherpereel, Astoul, Baas, Berghmans, Clayson, de Vuyst, Dienemann, Galateau-Salle, Hennequin, Hillerdal, Le Pechoux, Mutti, Pairon, Stahel, van Houtte, van Meerbeeck, et al: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010; 35: 479-495.
4. Sculier, Berghmans, Meert: Update in lung cancer and mesothelioma 2009. Am J Respir Crit Care Med. 2010; 181: 773-781.
5. Christensen, Houseman, Godleski, Marsit, Longacker, Roelofs, Karagas, Wrensch, Yeh, Nelson, Wiemels, Zheng, Wiencke, Bueno, Sugarbaker, Kelsey: Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 2009; 69: 227-234.
6. Liloglou, Bediaga, Brown, Field, Davies: Epigenetic biomarkers in lung cancer. Cancer Lett. 2012; 7.
7. Paik, Krug: Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol. 2010; 5: 275-279.
8. Martinet, Bertrand: Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag Res. 2011; 3: 117-141.
9. Bolden, Peart, Johnstone: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-784.
10. Weichert: HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009; 280: 168-176.
11. Witt, Deubzer, Milde, Oehme: HDAC family: What are the cancer relevant targets? Cancer Lett. 2009; 277: 8-21.
12. Glozak, Seto: Histone deacetylases and cancer. Oncogene. 2007; 26: 5420-5432.
13. Lane, Chabner: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009; 27: 5459-5468.
14. Khan, Jeffers, Kumar, Hackett, Boldog, Khramtsov, Qian, Mills, Berghs, Carey, Finn, Collins, Tumber, Ritchie, Jensen, Lichenstein, et al: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008; 409: 581-589.
15. Duvic, Vu: Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007; 16: 1111-1120.
16. Grant, Rahman, Piekarz, Peer, Frye, Robey, Gardner, Figg, Bates: Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010; 10: 997-1008.
17. Frikeche, Peric, Brissot, Gregoire, Gaugler, Mohty: Impact of HDAC inhibitors on dendritic cell functions. Exp Hematol. 2012; 40: 783-791.
18. Blanquart, Francois, Charrier, Bertrand, Gregoire: Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds. Curr Cancer Drug Targets. 2011; 11: 919-928.
19. Charrier, Clarhaut, Gesson, Estiu, Wiest, Roche, Bertrand: Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. J Med Chem. 2009; 52: 3112-3115.
20. Hirayama, Tabata, Tabata, Maeda, Yasumitsu, Yamada, Kuribayashi, Fukuoka, Nakano: Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med. 2011; 105: 137-142.
21. Chatterjee, Heukamp, Siobal, Schottle, Wieczorek, Peifer, Frasca, Koker, Konig, Meder, Rauh, Buettner, Wolf, Brekken, Neumaier, Christofori, et al: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. 2013; 123: 1732-1740.
22. Vandermeers, Hubert, Delvenne, Mascaux, Grigoriu, Burny, Scherpereel, Willems: Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res. 2009; 15: 2818-2828.
23. Hubaux, Vandermeers, Crisanti, Kapoor, Burny, Mascaux, Albelda, Willems: Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy. Eur J Cancer. 2010; 46: 1724-1734.
24. Osada, Tatematsu, Saito, Yatabe, Mitsudomi, Takahashi: Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 2004; 112: 26-32.
25. Sasaki, Moriyama, Nakashima, Kobayashi, Kiriyama, Fukai, Yamakawa, Fujii: Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004; 46: 171-178.
26. Lee, Choy, Ngo, Venta-Perez, Marks: Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci U S A. 2011; 108: 19629-19634.
27. Lopez, Torres, Liu, Hernandez, Young, Belousov, Bolshakov, Lazar, Slopis, McCutcheon, McConkey, Lev: Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011; 71: 185-196.
28. Epping, Meijer, Bos, Bernards: UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid. Mol Cancer Res. 2009; 7: 1861-1870.
29. Okada, Tanaka, Nakatani, Sakimura, Matsunobu, Li, Hanada, Nakamura, Oda, Tsuneyoshi, Iwamoto: Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer. 2006; 118: 90-97.
30. Qiu, Burgess, Fairlie, Leonard, Parsons, Gabrielli: Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell. 2000; 11: 2069-2083.
31. Taddei, Maison, Roche, Almouzni: Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat Cell Biol. 2001; 3: 114-120.
32. Robbins, Jablonski, Yen, Yoda, Robey, Bates, Sackett: Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle. 2005; 4: 717-726.
33. Stevens, Beamish, Warrener, Gabrielli: Histone deacetylase inhibitors induce mitotic slippage. Oncogene. 2008; 27: 1345-1354.
34. Ohira, Gemmill, Ferguson, Kusy, Roche, Brambilla, Zeng, Baron, Bemis, Erickson, Wilder, Rustgi, Kitajewski, Gabrielson, Bremnes, Franklin, et al: WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci U S A. 2003; 100: 10429-10434.
35. Potiron, Roche, Drabkin: Semaphorins and their receptors in lung cancer. Cancer Lett. 2009; 273: 1-14.
36. Dickinson, Johnstone, Prince: Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs. 2010; 28 Suppl 1: S3-20.
37. Mie Lee, Kim, Kim, Jin Son, Nakajima, Jeong Kwon, Kim: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun. 2003; 300: 241-246.
38. Planchard, Le Pechoux: Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer. 2011; 47 Suppl 3: S272-283.
39. Vogelzang, Rusthoven, Symanowski, Denham, Kaukel, Ruffie, Gatzemeier, Boyer, Emri, Manegold, Niyikiza, Paoletti: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 2636-2644.
40. van Meerbeeck, Gaafar, Manegold, Van Klaveren, Van Marck, Vincent, Legrand, Bottomley, Debruyne, Giaccone: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005; 23: 6881-6889.
41. Barbone, Cheung, Battula, Busacca, Gray, Longley, Bueno, Sugarbaker, Fennell, Broaddus: Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PLoS One. 2012; 7: e52753.
42. Gueugnon, Leclercq, Blanquart, Sagan, Cellerin, Padieu, Perigaud, Scherpereel, Gregoire: Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol. 2011; 178: 1033-1042.